The first product is expected to be launched shortly, while approvals
for the remaining are expected in the next 12-18 months, Caplin Point
Laboratories said in a BSE filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/caplin-point-labs-subsidiary-inks-distribution-pact-with-xellia-pharma-for-5-injectables-in-us/articleshow/76827893.cms
No comments:
Post a Comment